BCL-2 inhibition is a promising therapeutic strategy for small cell lung cancer
Oncoscience
.
2018 Aug 14;5(7-8):218-219.
doi: 10.18632/oncoscience.455.
eCollection 2018 Jul.
Authors
Timothy L Lochmann
1
,
Ynes M Bouck
1
,
Anthony C Faber
1
Affiliation
1
Anthony Faber: Philips Institute for Oral Health Research, Virginia Commonwealth University School of Dentistry and Massey Cancer Center, Richmond, VA, USA.
PMID:
30234143
PMCID:
PMC6142900
DOI:
10.18632/oncoscience.455
No abstract available
Keywords:
BCL-2 apoptosis; SCLC; targeted therapy.